August 28, 2026 07:27 am (IST)
Follow us:
facebook-white sharing button
twitter-white sharing button
instagram-white sharing button
youtube-white sharing button
Kanpur plane crash: Training aircraft crashes near Ganges, two pilots killed | Big IT boost for Bengal: LTM opens global delivery & AI centre in Kolkata's New Town | 21-year-old Delhi model found stabbed at Delhi home, gym trainer accused of killing her | ‘Who is stopping her from wearing what she wants?’: Kangana Ranaut hits back at Kriti Sanon over Raksha Bandhan ad | 300 Indians missing in Nepal flash floods, 160 dead: Foreign Minister reveals grim toll | Supreme Court directs Tarun Tejpal to surrender within two weeks | Supreme Court notice to 20 rebel TMC MPs in disqualification plea | ‘Reservation for poor, not caste’: Stir at Delhi’s Jantar Mantar | Dalit woman 'gangrape-murder' shocker in Karnataka: 4 arrested after body found in well | India dismisses Pakistan's 'frustration' over US envoy's J&K remark

Singapore to begin human clinical trials on potential coronavirus treatment - Reports

| @indiablooms | Jun 10, 2020, at 04:26 pm

Moscow/Sputnik/UNI: Singapore will begin human clinical trials on a domestically developed treatment candidate for the coronavirus next week, media reported Wednesday.

According to the Singapore news outlet, The Strait Times, biotechnology company Tychan will administer the experimental treatment to 23 healthy individuals and monitor the results over six weeks.

The medication in question is the TY027, which was developed to specifically target Sars-Cov-2, the virus that causes COVID-19, the newspaper reported.

The medication is being studied for qualities of slowing the spread of the virus, speeding up recovery and even protecting against the infection, according to The Strait Times.

Tychan is one of the dozens of companies around the world racing to develop treatments and vaccines against the coronavirus, which has so far infected more than 7.3 million people and killed over 410,000. 

Support Our Journalism

We cannot do without you.. your contribution supports unbiased journalism

IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.

Support objective journalism for a small contribution.